Metastatic breast cancer is an incurable disease and identification of novel therapeutic opportunities is vital. Triple-negative breast cancer (TNBC) frequently metastasizes and high levels of activated p90RSK (RSK), a downstream MEK-ERK1/2 effector, are found in TNBC. We demonstrate, using direct pharmacologic and genetic inhibition of RSK1/2, that these kinases contribute to the TNBC metastatic process in vivo Kinase profiling showed that RSK1 and RSK2 are the predominant kinases targeted by the new inhibitor, which is based on the natural product SL0101. Further evidence for selectivity was provided by the observations that silencing RSK1 and RSK2 eliminated the ability of the analogue to further inhibit survival or proliferation of a TNBC cell line. In vivo, the new derivative was as effective as the FDA-approved MEK inhibitor trametinib in reducing the establishment of metastatic foci. Importantly, inhibition of RSK1/2 did not result in activation of AKT, which is known to limit the efficacy of MEK inhibitors in the clinic. Our results demonstrate that RSK is a major contributor to the TNBC metastatic program and provide preclinical proof-of-concept for the efficacy of the novel SL0101 analogue in vivo Mol Cancer Ther; 15(11); 2598-608. ©2016 AACR.
©2016 American Association for Cancer Research.
Conflict of interest statement
Y-box Binding protein-1 Serine 102 Is a Downstream Target of p90 Ribosomal S6 Kinase in Basal-Like Breast Cancer Cells
AL Stratford et al.
Breast Cancer Res 10 (6), R99.
We therefore conclude that RSK1/RSK2 are novel activators of YB-1, able to phosphorylate the serine 102 residue. This provides a newly described mechanism whereby YB-1 is …
Luteolin Is a Novel p90 Ribosomal S6 Kinase (RSK) Inhibitor That Suppresses Notch4 Signaling by Blocking the Activation of Y-box Binding protein-1 (YB-1)
KM Reipas et al.
Oncotarget 4 (2), 329-45.
Triple-negative breast cancers (TNBC) are notoriously difficult to treat because they lack hormone receptors and have limited targeted therapies. Recently, we demonstrate …
Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-box Binding protein-1 in Triple-Negative Breast Cancers
AL Stratford et al.
Stem Cells 30 (7), 1338-48.
Y-box binding protein-1 (YB-1) is the first reported oncogenic transcription factor to induce the tumor-initiating cell (TIC) surface marker CD44 in triple-negative breas …
Targeting RSK2 in Human Malignancies
S Kang et al.
Expert Opin Ther Targets 15 (1), 11-20.
The significance of RSK2 in cancer cell survival, proliferation, invasion and tumor metastasis varies amongst human malignancies and depends on the signaling properties o …
Selective Targeting of RSK Isoforms in Cancer
KA Casalvieri et al.
Trends Cancer 3 (4), 302-312.
The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The …
PubMed Central articles
Clinicopathological Significance of Ribosomal Protein S6 Kinase A6 in Lung Squamous Cell Carcinoma: An Immunohistochemical and RNA-seq Study
YY Fang et al.
Int J Clin Exp Pathol 11 (3), 1318-1327.
Ribosomal protein S6 kinase A6 (RPS6KA6) is a downstream factor of the ERK-MAPK pathway and has been extensively studied in various types of cancer. However, the role of …
Inhibition of p90RSK Activation Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin by Inhibiting Proliferation, Migration and EMT
Y Jin et al.
BMB Rep 52 (12), 706-711.
Cisplatin (Cis-DDP) is one of the most widely used anti-cancer drugs. It is applicable to many types of cancer, including lung, bladder, and breast cancer. However, its u …
Synthesis and Direct Comparison of the Anticancer Activities of Phomopsolides D and E and Two 7-oxa-/7-aza-analogues
AZ Aljahdali et al.
Medchemcomm 10 (7), 1205-1211.
The synthesis of two stable phomopsolide natural products (D and E) and two analogues is presented. The cytotoxicities of these four compounds are surveyed and compared a …
HMGA1 Modulates Gene Transcription Sustaining a Tumor Signalling Pathway Acting on the Epigenetic Status of Triple-Negative Breast Cancer Cells
C Penzo et al.
Cancers (Basel) 11 (8).
Chromatin accessibility plays a critical factor in regulating gene expression in cancer cells. Several factors, including the High Mobility Group A (HMGA) family members, …
Role of p90RSK in Kidney and Other Diseases
L Lin et al.
Int J Mol Sci 20 (4).
The 90 kDa ribosomal s6 kinases (RSKs) are a group of serine/threonine kinases consisting of 4 RSK isoforms (RSK1-4), of which RSK1 is also designated as p90RSK. p90RSK p …
LinkOut - more resources
Full Text Sources